Capital Asset Advisory Services LLC Has $4.52 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Capital Asset Advisory Services LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.1% in the fourth quarter, Holdings Channel reports. The firm owned 7,289 shares of the medical research company’s stock after selling 1,295 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $4,524,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Highline Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after acquiring an additional 33 shares in the last quarter. Capital A Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 66 shares during the period. Cloud Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $31,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $33,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $478.29 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $540.67 and its 200-day moving average is $548.27. The firm has a market capitalization of $177.67 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 2.74 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the business posted $6.10 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be given a dividend of $0.47 per share. The ex-dividend date is Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.60%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. TD Cowen cut their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a report on Friday, January 30th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.